TY  - GEN
AU  - O'Malley,David M
AU  - Matulonis,Ursula A
AU  - Birrer,Michael J
AU  - Castro,Cesar M
AU  - Gilbert,Lucy
AU  - Vergote,Ignace
AU  - Martin,Lainie P
AU  - Mantia-Smaldone,Gina M
AU  - Martin,Antonio González
AU  - Bratos,Raquel
AU  - Penson,Richard T
AU  - Malek,Karim
AU  - Moore,Kathleen N
TI  - Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
SN  - 1095-6859
PY  - 2020///1030
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bevacizumab
KW  - Carcinoma, Ovarian Epithelial
KW  - drug therapy
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Folate Receptor 1
KW  - immunology
KW  - Humans
KW  - Immunoconjugates
KW  - Maytansine
KW  - Middle Aged
KW  - Organoplatinum Compounds
KW  - pharmacology
KW  - Ovarian Neoplasms
KW  - Progression-Free Survival
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.ygyno.2020.01.037
ER  -